Adverum Biotechnologies, Inc. (ADVM)
ADVM Stock Price Chart
Explore Adverum Biotechnologies, Inc. interactive price chart. Choose custom timeframes to analyze ADVM price movements and trends.
ADVM Company Profile
Discover essential business fundamentals and corporate details for Adverum Biotechnologies, Inc. (ADVM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
31 Jul 2014
Employees
155.00
Website
https://www.adverum.comCEO
Laurent Fischer
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
ADVM Financial Timeline
Browse a chronological timeline of Adverum Biotechnologies, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
Upcoming earnings on 5 May 2026
Upcoming earnings on 3 Nov 2025
EPS estimate is -$1.65.
Earnings released on 12 Aug 2025
EPS came in at -$2.34 falling short of the estimated -$2.24 by -4.46%.
Earnings released on 15 Apr 2025
EPS came in at -$1.96 falling short of the estimated -$1.81 by -8.29%.
Earnings released on 24 Mar 2025
EPS came in at -$1.57 falling short of the estimated -$1.31 by -20.12%, while revenue for the quarter reached -$3.60M .
Earnings released on 4 Nov 2024
EPS came in at -$1.30 falling short of the estimated -$1.20 by -8.33%, while revenue for the quarter reached $1.00M , beating expectations by +700.00%.
Earnings released on 12 Aug 2024
EPS came in at -$0.89 surpassing the estimated -$1.27 by +29.92%.
Earnings released on 9 May 2024
EPS came in at -$1.50 falling short of the estimated -$1.28 by -17.19%.
Stock split effective on 21 Mar 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 18 Mar 2024
EPS came in at -$2.30 surpassing the estimated -$2.80 by +17.86%, while revenue for the quarter reached -$3.60M .
Earnings released on 9 Nov 2023
EPS came in at -$3.30 falling short of the estimated -$3.00 by -10.00%.
Earnings released on 10 Aug 2023
EPS came in at -$3.10 surpassing the estimated -$3.20 by +3.13%.
Earnings released on 11 May 2023
EPS came in at -$2.90 surpassing the estimated -$3.00 by +3.33%, while revenue for the quarter reached $3.60M .
Earnings released on 30 Mar 2023
EPS came in at -$3.30 falling short of the estimated -$3.20 by -3.12%.
Earnings released on 10 Nov 2022
EPS came in at -$4.00 falling short of the estimated -$3.20 by -25.00%.
Earnings released on 11 Aug 2022
EPS came in at -$4.40 falling short of the estimated -$3.80 by -15.79%.
Earnings released on 12 May 2022
EPS came in at -$3.80 falling short of the estimated -$3.40 by -11.76%.
Earnings released on 29 Mar 2022
EPS came in at -$3.50 surpassing the estimated -$4.20 by +16.67%, while revenue for the quarter reached -$7.50M .
Earnings released on 4 Nov 2021
EPS came in at -$3.90 surpassing the estimated -$4.20 by +7.14%.
Earnings released on 5 Aug 2021
EPS came in at -$4.50 falling short of the estimated -$3.70 by -21.62%.
Earnings released on 6 May 2021
EPS came in at -$2.90 surpassing the estimated -$3.80 by +23.68%, while revenue for the quarter reached $7.50M , beating expectations by +12.40K%.
Earnings released on 1 Mar 2021
EPS came in at -$3.90 falling short of the estimated -$3.20 by -21.87%.
Earnings released on 5 Nov 2020
EPS came in at -$3.10 surpassing the estimated -$3.50 by +11.43%.
ADVM Stock Performance
Access detailed ADVM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.